

UBS (Lux) Digital Health Equity Fund SB USD



Fund information

Equity

1'123'155'240

Fund total net assets in USD

Share class TNA, USD 43'862'656	Share class NAV, USD 1'564.58	Management fee p.a. ¹ 0.40%
---	---	--

MTD (net) return 1.79% Bench. 1.89%	QTD (net) return 10.29% Bench. 5.23%	YTD (net) return 1.71% Bench. 18.80%
---	--	--

Fund details

Investment Manager	Thomas Amrein, Fang Liu
Fund launch date	14.12.2017
Share class launch date	14.12.2017
Share class	SB
Share class currency	USD
Distribution policy	Accumulating
Fund domicile	Luxembourg
ISIN	LU1683288002
Benchmark	MSCI World ESG Leaders (NR)


Investment Policy

Health care cost to society has risen to levels which are no longer sustainable. This fund invests globally in innovative companies which are driving a revolution in the health care sector through the application of technology. It offers diversified exposure to the digital health universe, which is one of the fastest growing segments in the health care industry. The investment universe comprises three segments: Research & Development, Treatments and Efficiency. The fund invests in "pure-play" digital health companies, which are typically small to mid-sized. The investment objective is long-term capital appreciation from actively managed exposure to this secular growth theme.

Investing involves risk including the risk of loss of capital. Past performance does not predict future returns. Neither simulated nor historical performance is a reliable indicator for current or future performance.


Performance overview - monthly & cumulative

since 01.01.2024



Performance overview - cumulative

since 01.01.2018



Performance overview - monthly & YTD

since 01.01.2024, in %

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD
Portfolio net	-4.61	7.71	-1.03	-10.47	0.00	1.30	5.91	2.31	1.79				1.71
Benchmark	1.74	4.28	3.43	-3.90	4.54	2.40	0.90	2.36	1.89				18.80
Relative net	-6.36	3.43	-4.46	-6.57	-4.55	-1.09	5.01	-0.05	-0.10				-17.09

Performance overview - yearly

since 01.01.2018, in %

	2018	2019	2020	2021	2022	2023	2024
Portfolio net	3.80	34.78	88.82	-18.81	-35.53	9.83	1.71
Benchmark	-8.69	28.42	15.30	24.70	-19.57	25.40	18.80
Relative net	12.50	6.36	73.52	-43.51	-15.96	-15.57	-17.09

¹ If the currency of a financial product and/or its costs is different from your reference currency, the return and cost may increase or decrease as a result of currency fluctuations. The individuals mentioned above only conduct regulated activities in the jurisdiction(s) where they are properly licensed, where relevant.

ESG stands for environmental (E), social (S), and governance (G).

Please find the definition of all the acronyms/terms used in this document in the Glossary. Additional important information can be found at the end of the document.

Performance overview

since 01.01.2018, in %

	Rolling Returns		Annualized Returns			
	1 months	3 months	1 year	3 years	5 years	ITD
Portfolio net	1.79	10.29	18.58	-14.17	5.55	6.65
Benchmark	1.89	5.23	32.89	9.37	13.29	10.98
Relative net	-0.10	5.06	-14.31	-23.54	-7.75	-4.33

Risk overview - ex post

since 01.01.2018, in %

	Annualized risk, in %			
	1 year	3 years	5 years	ITD
Portfolio volatility	30.80	29.60	28.64	27.53
Benchmark volatility	12.58	17.45	17.73	16.85
Tracking error	21.20	20.04	20.75	19.47

Potential Risks

The Fund's risk and reward profile does not reflect the risk inherent in future circumstances that differ from what the Fund has experienced in the recent past. This includes the following events which are rare but can have a large impact.

- **Credit risk:** Issuers of assets held by the Fund may not pay income or repay capital when due. The Fund's investments have low credit risk.
- **Liquidity risk:** Assets cannot necessarily be sold at limited cost in an adequately short timeframe. The Fund's investments may be prone to limited liquidity. The Fund will endeavor to mitigate this risk by various measures.
- **Counterparty risk:** Bankruptcy or insolvency of the Fund's derivative counterparties may lead to payment or delivery default.
- **Operational risk:** Deficient processes, technical failures or catastrophic events may cause losses.
- **Political and Legal risks:** Investments are exposed to changes of rules and standards applied by a specific country. This includes restrictions on currency convertibility, the imposing of taxes or controls on transactions, the limitations of property rights or other legal risks.
- **Sustainability risks:** Sustainability risks are environmental, social or governance events or conditions that can have a material negative effect on the return, depending on the relevant sector, industry and company exposure.

The product's investment objectives, risks, charges and expenses, as well as more complete information about the product, are provided in the prospectus (or relevant offering document), which should be read carefully before investing.

Investors may lose part or all of their invested amount. The investment promoted in this marketing material concerns the acquisition of units or shares in a fund and not of any underlying assets. The underlying assets are owned by the fund only. Any decision to invest should take into account all the characteristics or objectives of the promoted fund as described in its prospectus, or similar legal documentation.

Asset breakdown by subtheme

In % of total economic exposure

	in %	Portfolio
Treatments	45.95	
Efficiency	30.45	
R&D	23.62	
Cash/Cash Equivalents	0.01	

Asset breakdown by risk currency

In % of total economic exposure

	in %	Portfolio
USD	69.39	
CNY	7.85	
JPY	6.99	
EUR	4.93	
DKK	3.96	
CHF	2.85	
ILS	1.85	
CAD	1.04	
GBP	0.95	
HKD	0.17	


Asset breakdown by risk country

In % of total economic exposure

	in %	Portfolio
United States	69.70	
China	7.85	
Japan	6.99	
Netherlands	4.04	
Denmark	3.96	
Switzerland	2.85	
Israel	1.85	
Canada	1.04	
Jersey, Channel Islands	0.95	
Others	0.77	

Risk profile²

PRIIP SRI



Larger values (up to 7) indicate higher risk while lower values (up to 1) indicate lower risk.

Key figures

	Portfolio	Benchmark
Number of securities	53	697

Fund Statistics - ex post

	1 year		3 years		5 years	
	Portfolio	Benchmark	Portfolio	Benchmark	Portfolio	Benchmark
Beta						
			Relative	Relative	Relative	Relative
			2.08	1.28	1.12	
Information ratio			-0.38	-1.06	-0.22	
Maximum drawdown, in %	-13.08	-3.90	-54.17	-27.00	-59.96	-27.00

² The risk indicator assumes you keep the Product for 7 years. The actual risk can vary significantly if you redeem at an early stage and you may get back less. The Summary Risk Indicator is a guide to the level of risk of this Product compared to other products. It shows how likely it is that the Product will lose money because of movements in the markets. Be aware of currency risk if your reference currency differs from the currency of the Product. You may receive payments in a different currency, so the final return you will get depends on the exchange rate between the two currencies. Investors shall note that the Product may be exposed to further risks such as operational, counterparty, political, sustainability and legal risks that are not included in the Summary Risk Indicator. This Product does not include any protection from future market performance so you could lose some or all of your investment.

Past performance does not predict future returns. Neither simulated nor historical performance is a reliable indicator for current or future performance.

Largest contributors and detractors

MTD as of 30.09.2024

Contributors ³	Total return	Weight	Portfolio		Detractors ³	Total return	Weight	Portfolio	
			Total effect					Total effect	
JD HEALTH INTERNATIONAL INC	49.25%	2.20%	1.04%		ARROWHEAD PHARMACEUTICALS INC	-18.72%	2.28%	-0.47%	
ZAI LAB LTD	25.27%	4.32%	1.01%		SCHRODINGER INC	-11.79%	3.57%	-0.44%	
INSPIRE MEDICAL SYSTEMS INC	17.46%	3.77%	0.62%		PHREESIA INC	-11.33%	3.08%	-0.38%	
DENALI THERAPEUTICS INC	19.16%	3.44%	0.58%		EVOLVENT HEALTH INC CLASS A	-11.55%	3.04%	-0.37%	
DOXIMITY INC CLASS A	18.45%	3.13%	0.55%		IOVANCE BIOTHERAPEUTICS INC	-19.47%	1.44%	-0.32%	

Largest contributors and detractors

QTD as of 30.09.2024

Contributors ³	Total return	Weight	Portfolio		Detractors ³	Total return	Weight	Portfolio	
			Total effect					Total effect	
INSPIRE MEDICAL SYSTEMS INC	57.65%	3.80%	1.91%		DEXCOM INC	-40.87%	2.75%	-1.47%	
EXACT SCIENCES CORP	60.66%	3.55%	1.80%		IRHYTHM TECHNOLOGIES INC	-31.03%	2.04%	-0.86%	
ZAI LAB LTD	42.44%	4.15%	1.71%		ARROWHEAD PHARMACEUTICALS INC	-25.47%	2.58%	-0.76%	
DOXIMITY INC CLASS A	55.49%	2.87%	1.47%		UROGEN PHARMA LTD	-24.31%	1.72%	-0.50%	
JD HEALTH INTERNATIONAL INC	65.55%	1.97%	1.35%		MODERNA INC	-43.05%	0.83%	-0.48%	

Largest contributors and detractors

YTD as of 30.09.2024

Contributors ³	Total return	Weight	Portfolio		Detractors ³	Total return	Weight	Portfolio	
			Total effect					Total effect	
TRANSMEDICS GROUP INC	97.78%	3.86%	2.87%		10X GENOMICS INC CLASS A	-59.61%	3.42%	-3.07%	
ZEALAND PHARMA	120.32%	3.67%	2.77%		SCHRODINGER INC	-48.05%	3.52%	-2.20%	
NATERA INC	102.53%	3.76%	2.67%		DEXCOM INC	-45.95%	2.99%	-1.67%	
SHOCKWAVE MEDICAL INC	71.02%	1.64%	2.10%		INARI MEDICAL INC	-36.53%	2.47%	-1.04%	
DOXIMITY INC CLASS A	55.08%	2.42%	1.37%		ARROWHEAD PHARMACEUTICALS INC	-36.82%	2.44%	-1.02%	

Performance commentary

Our strategy strongly outperformed the benchmark in Q3, driven by strong rebound of the efficiency sub-theme and continued robust performance in the treatment sub-theme. The top three performance contributors were Inspire Medical, Exact Sciences and Zai Lab. Inspire delivered a strong beat-and-raise Q2, defying market concern around GLP-1 impact with reassuring margin trends. Exact Sciences posted strong Cologuard growth and improving margin in Q2, followed by an encouraging blood-based colorectal cancer screening test clinical trial in September. Zai Lab had a strong rebound after China stimulus announced at the end of September. The top three performance detractors were Dexcom, iRythm and Arrowhead. Dexcom slumped after major execution hiccups in Q2. iRythm was weak due to lingering overhang around US Food and Drug Administration (FDA) inspection on its manufacturing facilities, but fundamentals were strong. Arrowhead was weak due to financing concerns which were later relieved.

Market comments

Q3 was a bumpy ride towards another all-time high for major equity indices. Softer US inflation prints in June and cooler July non-farm payroll drove markets out of growth names into small and mid cap names in July, leading to Digital Health strategy outperformance. This was quickly followed by a sharp sell-off in early August amid concerns of a hard landing in the US and fear that the FED was behind the curve. But markets quickly rebounded as the FED soon reaffirmed its intention to cut rate in September as well as its strong willingness to support a strong labour market. As the FED commenced with a 50bp cut in September (Press Release, 18.09.2024) and markets continued to price in further cuts in the remainder of the year, the soft-landing narrative remained intact, which supported another strong equity market performance in September.

Comments on transactions

We did not enter or exit any positions in Q3. We continued to do rebalancing alongside market volatilities.

This commentary is intended only to describe past performance of the investment strategy. The strategy invests in individual securities which are owned in the strategy as part of a carefully constructed and diversified portfolio. The information presented in this commentary may be based on the assessment of UBS' portfolio managers. Market developments described in this document are subject to a number of risks and uncertainties and are neither reliable indicators nor a guarantee of future results/performance. The information in this commentary may change after the date of issuance of this document without notice and should not be construed as a recommendation to buy or sell individual securities named herein.

³ This is an indicative allocation which may change over time. This product is not a direct investment the collaterals displayed above. As a result, it does not reflect the actual performance of the product either positively or negatively. The individual entities and/or instruments mentioned on this page are meant for illustration purposes only and are not intended as a solicitation or an offer to buy or sell any interest or any investment.

Key identifiers

Instrument Name	UBS (Lux) Digital Health Equity Fund SB USD
ISIN	LU1683288002
Bloomberg ticker	CSGDSBU LX
Valor no.	38312197
Benchmark	MSCI World ESG Leaders (NR)
Benchmark Bloomberg ticker	NGSINU

Key facts

Fund management company	UBS Asset Management (Europe) S.A.
UCITS	Yes
SFDR Classification ⁴	Article 8
Accounting year end	31. May
Securities lending	Yes
Ongoing charges ⁵	0.65%
Subscription frequency	daily
Subscription settlement period	T + 2
Redemption frequency	daily
Redemption settlement period	T + 2
Cut-off time	15:00 CET
Swinging single pricing (SSP*)	partial swing NAV

ESG Approach

This fund promotes environmental, social and governance (ESG) characteristics (within the meaning of Art. 8 of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector). It applies the CSAM Sustainable Investing Policy (www.credit-suisse.com/esg), including norms-based, values-based and business conduct exclusions, to combine ESG factors with traditional financial analysis to make an ESG adjusted risk-return assessment, which serves as the basis for the portfolio construction. For further information about the ESG investment criteria and the sustainability-related aspects of the fund please consider the legal and regulatory documents of the fund (such as, e.g., the prospectus) and visit www.credit-suisse.com/esg. In addition to sustainability-related aspects, the decision to invest in the fund should take into account all objectives and characteristics of the fund as described in its prospectus, or in the information which is to be disclosed to investors in accordance with applicable regulations.

Certain data points are provided for mere transparency purposes and are not linked to a specific ESG investment process. For details about the fund's ESG decision-making process, please refer to the fund's prospectus.

ESG Characteristics

ESG Benchmark	Exclusion Criteria	ESG Integration	Active Ownership ⁶	Sustainable Investment Objective
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>

ESG Overview

According to MSCI methodology. Fund performance against benchmark: MSCI World ESG Leaders (NR).

	Portfolio	Benchmark
ESG Rating	BBB	AA
ESG Quality score	5.59	7.89
Environmental score	6.02	6.56
Social score	4.45	5.59
Governance score	6.04	5.93
Coverage for Rating/Scoring	96.13%	100.00%
Weighted Average Carbon Intensity (Tons of CO ₂ e/\$M sales)	19.53	61.11
Coverage for Carbon Intensity	95.88%	100.00%

Note: The total carbon intensity figure shown in this section may be higher than the total in the breakdown graph. This is because the figure is normalized, and actual weights are inflated because of limited data coverage. For further information on the MSCI methodology for the above listed ESG data points, please refer to the glossary.

Top 10 positions - ESG Characteristics

In terms of the fund's total economic exposure. Certain data points disclosed in this table are provided for mere transparency purposes and are not linked to a specific ESG investment process. For details about the fund's ESG decision-making process, please refer to the fund's prospectus. Source: MSCI

Instrument Name ⁷	Weight in portfolio	GICS sector	MSCI ESG Rating	Controversy flag	Carbon intensity (tCO ₂ e / \$M sales)
ZAI LAB LTD	4.74%	Health Care	BBB	Green	18.40
NATERA INC	4.08%	Health Care	BB	Green	12.60
REDCARE PHARMACY NV	4.04%	Consumer Staples	AAA	Green	1.84
ZEALAND PHARMA	3.96%	Health Care	BBB	Green	49.70
TRANSMEDICS GROUP INC	3.85%	Health Care	BB	Green	15.60
VEEVA SYSTEMS INC CLASS A	3.84%	Health Care	AA	Green	0.21
INSPIRE MEDICAL SYSTEMS INC	3.77%	Health Care	BBB	Green	14.13
EXACT SCIENCES CORP	3.65%	Health Care	A	Yellow	12.50
DENALI THERAPEUTICS INC	3.46%	Health Care	A	Green	49.70
10X GENOMICS INC CLASS A	3.43%	Health Care	BBB	Green	11.70

Note: All ESG data points in the table refer to an underlying issuer as applicable (e.g., an equity issuer in case of a convertible bond). For further information on the methodology for the above listed ESG data points, please refer to the glossary.

⁴ CS Product Sustainability Classifications and SFDR Article are valid at the time of publishing and may be subject to change.

⁵ If the currency of a financial product and/or its costs is different from your reference currency, the return and cost may increase or decrease as a result of currency fluctuations.

⁶ Active Ownership is part of the fund's strategy to act in the best interests of its investors and to preserve and optimize the long-term value of their investments. To promote best practices and to ensure that the investee companies are sustainable and successful in the long term, Active Ownership is designed to influence the investee companies on two levels: first, through proxy voting, and second, through engagement. In the case of investments in other funds (Target Funds), the fund has no or only limited ability to exercise Active Ownership on the Target Fund, resp. on the Target Funds' investee companies.

⁷ This is an indicative allocation which may change over time. This product is not a direct investment the collaterals displayed above. As a result, it does not reflect the actual performance of the product either positively or negatively. The individual entities and/or instruments mentioned on this page are meant for illustration purposes only and are not intended as a solicitation or an offer to buy or sell any interest or any investment.

Asset breakdown by ESG rating

In % of total economic exposure. Fund performance against benchmark: MSCI World ESG Leaders (NR). Source: MSCI ESG rating

	Portfolio	Benchmark	Portfolio Benchmark
AAA	4.04	28.90	
AA	8.65	43.09	
A	22.40	18.65	
BBB	41.77	9.00	
BB	13.96	0.36	
B	3.97	-	
CCC	1.34	-	
Not ratable	-0.13	0.00	
No data coverage	4.00	-	

Note: For further information on MSCI's ESG rating methodology and the difference between categories "not ratable" and "no data coverage", please refer to the glossary.

Carbon emission intensity contribution by GICS sector

Tons of CO2 equivalent emission intensity (GHG scopes 1 & 2) per \$m sales, by GICS sector split. Fund performance against benchmark: MSCI World ESG Leaders (NR). Source: MSCI

	Portfolio	Benchmark	Portfolio Benchmark
Health Care	19.83	1.88	
Consumer Staples	0.08	2.82	
FX	0.00	0.00	
Cash	0.00	0.00	
Others	0.00	56.42	
Total	19.91	61.11	

Note: Security weighted data coverage is 95.88% for the portfolio. The total shown in this section may be lower than the one in the 'ESG Overview' section. This is because the figures in this breakdown are not normalized and use the actual weights. For further information on the Carbon emission intensity, please refer to the glossary.

Asset breakdown by ESG controversy flag

In % of fund total economic exposure to investee companies. Fund performance against benchmark: MSCI World ESG Leaders (NR). Source: MSCI

	Portfolio	Benchmark	Portfolio Benchmark
Green	86.94	33.06	
Yellow	10.12	50.91	
Orange	0.57	16.03	
Red	-	-	
No data coverage	2.50	-	

Note: Exposure to investee companies represents 100.13% of portfolio weight for this share class. MSCI only provides data on ESG controversies for corporate issuers. Any remaining instruments (e.g., government bonds) are excluded from this breakdown. For further information on MSCI's ESG controversy flag methodology, please refer to the glossary.

Glossary

Accumulating	Indicates a regular reinvestment of the dividends received in the portfolio itself
Annualized risk	Annualized risk is a statistic, which is used to measure the risk of a fund by describing the range of returns, which were achieved in the observation period are most likely to be achieved. Greater volatility implies greater risk.
Annualized return	A measure of how much an investment has increased on average each year during a specific period.
Beta	A measure of the volatility, or systematic risk, of a single security or fund in comparison to the market as a whole.
Carbon emission intensity	The weighted average emissions intensity, which is provided by MSCI ESG, divides the Scopes 1 & 2 emissions in tons of CO ₂ -equivalent by million \$ sales. Intensities are broken down by GICS sector and are security weighted.
ESG benchmark	A ticked 'ESG benchmark' box reflects that the ESG section in this document compares the ESG performance of the portfolio with an ESG index. In case the box is not ticked, this means that the ESG section in this document compares the ESG performance of the portfolio with a non-ESG index or that no comparison is performed due to a lack of a recognized benchmark. The investor shall read the legal documentation of the Fund to understand how the benchmark is used. In any case, a ticked 'ESG benchmark' box does not mean that the ESG benchmark is used to attain the ESG strategy of the fund.
ESG Controversy Flag	ESG Controversy Flag is designed to provide timely and consistent assessments of ESG controversies involving publicly traded companies and fixed income issuers. A controversy case is typically a one-off event such as an environmental oil spill, an accident, or allegations such as safety issues in a production facility. Controversy flags can be red, orange, yellow or green. Red indicates that a company is involved in one or more very severe controversies. Orange indicates that a company has been involved in one or more recent severe structural controversies that are ongoing. Yellow indicates that the company is involved in severe-to-moderate level controversies. Green indicates that the company is not involved in any major controversies. For further information on the methodology, please refer to www.msci.com/esg-investing .
ESG Quality score	The ESG Quality score, based on MSCI ESG scores of underlyings, is measured on a scale from 0 (very poor) to 10 (very good). It does not correspond directly to the underlying Environment, Social and Governance Pillar scores. The Pillar scores are derived on an absolute basis, while the portfolio ESG Quality score is adjusted by MSCI to reflect the industry-specific level of ESG risk exposure. As Pillar scores are absolute, and the portfolio ESG Quality score is relative, the first cannot be averaged to derive the latter. The coverage rate is security weighted.
Issuer ESG Rating	Company and Government ESG Ratings, which are provided by MSCI ESG, are measured on a scale from AAA (highest rating) to CCC (lowest rating). Company ESG Ratings are based on the issuer's exposure to industry specific ESG risks and its ability to mitigate those risks relative to peers. Company ESG Ratings are calculated on an industry relative basis while the underlying individual E, S and G Ratings are absolute. Hence, the ESG Rating cannot be seen as an average of the individual E, S and G Ratings. Government ESG Ratings identify a country's exposure to and management of ESG risk factors and explain how these factors might impact the long-term sustainability of its economy. They are derived from 0-10 scores on underlying factors in the E, S and G pillars. For further information on the MSCI methodology, please refer to www.msci.com/esg-investing .
Ex post	Refers to metrics based on historical data
GICS	Global Industry Classification Standard
Greenhouse gas (GHG) emissions	Scope 1 emissions are generated by a company directly from owned or controlled sources such as the burning of fuels (stationary or mobile), industrial processes, etc. Scope 2 emissions are indirect emissions, primarily those associated with the electricity consumed by a company. Scope 3 emissions are all other indirect emissions associated with a company's operations, such as business travel, waste generated, and products both upstream (in the supply chain) and downstream (use of the products and end of life). Scope 3 emissions typically account for the largest proportion of a company's emissions.
Information ratio	This statistic measures how much a fund's out-performance may be attributed to manager skill as oppose to market movement. A high Information Ratio infers more manager skill than a low value would suggest.
ITD	Inception-to-date
Maximum drawdown	Represents the worst possible result (in percentage terms) that occurred during the period being analyzed.
MTD	Month-to-date
MSCI	MSCI refers to the external data provider MSCI ESG Research LLC and/or its affiliates.
MSCI ESG Methodology	For further information on the methodology applied to assess the ESG characteristics of the investments, please refer to www.msci.com/esg-investing .
NAV	Net Asset Value
Not ratable / No data coverage	Where MSCI considers an asset type for ESG analysis but data on an economic exposure is unavailable due to a lack of data from the data vendor, the investment falls under the category "No data coverage". Where MSCI considers an asset type out of scope for ESG analysis (e.g. Cash, Currency), the economic exposure falls under the category "Not ratable". For further information regarding excluded asset types, please refer to www.msci.com/esg-investing .
Ongoing Charges	The calculation of the ongoing charge is based on the Committee of European Securities Regulators/10-674 Directive. For a maximum of 12 months from fund fiscal year end and since inception, the ongoing charges figure is based on estimated expenses. After that, the ongoing charges correspond to the TER of the last annual report. It excludes performance fees and portfolio transaction costs, except in the case of an entry/exit charge paid by the fund when buying or selling shares/units in another collective investment undertaking.
Portfolio/Benchmark ESG Rating	Discrepancies may exist between the portfolio-level ESG Rating calculated by UBS applying the MSCI methodology (provided in this factsheet) and the ESG Ratings displayed by other providers (e.g., MSCI ESG fund ratings). There are three main reasons for these potential deviations: (1) UBS uses updated month-end holdings data as basis for its calculation, (2) UBS consistently uses underlying issuer data where applicable (e.g., equity issuer in case of a convertible bond), and (3) look-through approach for target funds applied by UBS. The coverage rate is security weighted. For further information on the MSCI methodology, please refer to www.msci.com/esg-investing .
QTD	Quarter-to-date
Sustainable Finance Disclosure Regulation (SFDR)	Regulation (EU) 2019/2088 of the European Parliament and of the Council of 27 November 2019 on sustainability-related disclosures in the financial services sector
Swing Pricing	A method used to calculate the net asset values of investment funds. Which allows transaction costs arising from subscriptions made by incoming investors and redemptions made by outgoing investors to be borne by the incoming and outgoing investors, rather than existing investors.
Sustainable investment objective	Where the 'sustainable investment objective' box is ticked, this means that the product implements our investment strategies that allocate capital into companies that offer solutions to society's challenges and meet a sustainable investment objective. The sustainable investment objective is achieved through a dedicated investment process focusing on investments in themes and sectors whose economic activities address specific ESG challenges. An unticked box reflects that the product does not aim to meet a sustainable investment objective.
Sustainable thematic	This product undertakes investments that are dedicated to addressing the United Nations Sustainable Development Goals (e.g. education or clean energy) through a thematic approach.
TNA	Total Net Assets
Tracking error	Measure of the deviation of the return of a fund compared to the return of a benchmark over a fixed period of time.
YTD	Year-to-date

Warning statements

Asset breakdown	Indicative allocation may change over time. All holdings are shown strictly for information purposes only and do not constitute investment recommendations of UBS. Please note that this does not constitute an offer or a solicitation to buy or sell any interest or any investment.
Swinging Single Pricing	For more details, please refer to the relevant chapter "Net Asset Value" of the fund's prospectus
Performance start date	Performance calculation and presentation start with the first full month of an invested strategy. This can lead to a difference in launch and performance start dates.
PRIIP SRI	The Summary Risk Indicator is a guide to the level of risk of this Product compared to other products. It shows how likely it is that the Product will lose money because of movements in the markets.

For marketing and information purposes by UBS.

UBS Group funds under Luxembourg law.

Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s).

Before investing in a product please read the latest prospectus and key information document carefully and thoroughly.

Any decision to invest should take into account all the characteristics or objectives of the fund as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS Group funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The calculated performance takes all costs on the fund level into consideration (ongoing costs). The entry and exit costs, which would have a negative impact on the performance, are not taken into consideration. If whole or part of the total costs to be paid is different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations.

Commissions and costs have a negative impact on the investment and on the expected returns. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency and exchange rate fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS Asset Management Switzerland AG or a local affiliated company. Source for all data and charts (if not indicated otherwise): UBS Asset Management.

This document contains statements that constitute "forward-looking statements", including, but not limited to, statements relating to our future business development. While these forward-looking statements represent our judgments and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations.

Switzerland: Representative in Switzerland for UBS funds established under foreign law: UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. Paying agent: UBS Switzerland AG, Bahnhofstrasse 45, CH-8001 Zurich. Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, c/o UBS AG, Bahnhofstrasse 45, 8001 Zürich, Switzerland or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel.

Important information about sustainable investing strategies

Sustainable investing strategies aim to consider and incorporate environmental, social and governance (ESG) factors into investment process and fund construction. Strategies across geographies and styles approach ESG analysis and incorporate the findings in a variety of ways. Incorporating ESG factors or sustainable investing considerations may inhibit UBS's ability to participate in or to advise on certain investment opportunities that otherwise would be consistent with the Client's investment objectives. The returns on a fund consisting primarily of sustainable investments may be lower or higher than funds where ESG factors, exclusions, or other sustainability issues are not considered by UBS, and the investment instruments available to such funds may differ. Companies, product issuers and/or manufacturers may not necessarily meet high performance standards on all aspects of ESG or sustainable investing issues.

Although UBS Asset Management information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness of any data herein. None of the ESG Parties makes any express or implied warranties of any kind, and the ESG Parties hereby expressly disclaim all warranties of merchantability and fitness for a particular purpose, with respect to any data herein. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein. Further, without limiting any of the foregoing, in no event shall any of the ESG Parties have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

Certain information contained herein (the "Information") is sourced from/copyright of MSCI ESG Research LLC (a Registered Investment Adviser under the Investment Advisers Act of 1940), or its affiliates (including MSCI Inc. and its subsidiaries ("MSCI")), or third party suppliers (together with MSCI & MSCI ESG, the "ESG Parties") and may have been used to calculate scores, ratings or other indicators. It may not be reproduced or disseminated in whole or part without prior written permission. The Information has not been submitted to, nor received approval from, the US SEC or any other regulatory body. The Information may not be used to create any derivative works, or in connection with, nor does it constitute, an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product, trading strategy, or index, nor should it be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. Some funds may be based on or linked to MSCI indexes, and MSCI may be compensated based on the fund's assets under management or other measures. MSCI has established an information barrier between equity index research and certain Information. None of the Information in and of itself can be used to determine which securities to buy or sell or when to buy or sell them. The Information is provided "as is" and the user assumes the entire risk of any use it may make or permit to be made of the Information. No ESG Party warrants or guarantees the originality, accuracy and/or completeness of the Information and each expressly disclaims all express or implied warranties. No ESG Party shall have any liability for any errors or omissions in connection with any Information herein, or any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

A summary of investor rights in English can be found online at: ubs.com/funds.
More explanations of financial terms can be found at ubs.com/glossary.

© UBS 2024. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.